Annual EBITDA
-$235.03 M
-$274.12 M-701.29%
December 31, 2023
Summary
- As of February 8, 2025, RNAC annual EBITDA is -$235.03 million, with the most recent change of -$274.12 million (-701.29%) on December 31, 2023.
- During the last 3 years, RNAC annual EBITDA has fallen by -$168.45 million (-252.98%).
- RNAC annual EBITDA is now -701.29% below its all-time high of $39.09 million, reached on December 31, 2022.
Performance
RNAC EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$23.90 M
-$37.93 M-270.30%
September 1, 2024
Summary
- As of February 8, 2025, RNAC quarterly EBITDA is -$23.90 million, with the most recent change of -$37.93 million (-270.30%) on September 1, 2024.
- Over the past year, RNAC quarterly EBITDA has increased by +$32.74 million (+57.81%).
- RNAC quarterly EBITDA is now -180.09% below its all-time high of $29.84 million, reached on March 1, 2022.
Performance
RNAC Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$262.89 M
-$16.36 M-6.63%
September 1, 2024
Summary
- As of February 8, 2025, RNAC TTM EBITDA is -$262.89 million, with the most recent change of -$16.36 million (-6.63%) on September 1, 2024.
- Over the past year, RNAC TTM EBITDA has increased by +$8.13 million (+3.00%).
- RNAC TTM EBITDA is now -605.85% below its all-time high of $51.97 million, reached on June 1, 2022.
Performance
RNAC TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RNAC EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -701.3% | +57.8% | +3.0% |
| 3 y3 years | -253.0% | -459.2% | -772.6% |
| 5 y5 years | -273.9% | -459.2% | -772.6% |
RNAC EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -701.3% | at low | -180.1% | +87.8% | -605.9% | +3.0% |
| 5 y | 5-year | -701.3% | at low | -180.1% | +87.8% | -605.9% | +3.0% |
| alltime | all time | -701.3% | at low | -180.1% | +87.8% | -605.9% | +3.0% |
Cartesian Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$23.90 M(-270.3%) | -$262.89 M(+6.6%) |
| Jun 2024 | - | $14.03 M(-124.8%) | -$246.53 M(-9.0%) |
| Mar 2024 | - | -$56.64 M(-71.2%) | -$271.03 M(+15.3%) |
| Dec 2023 | -$235.03 M(-701.3%) | -$196.39 M(+2504.6%) | -$235.03 M(+634.6%) |
| Sep 2023 | - | -$7.54 M(-27.9%) | -$32.00 M(+1.5%) |
| Jun 2023 | - | -$10.46 M(-49.3%) | -$31.52 M(+176.5%) |
| Mar 2023 | - | -$20.65 M(-410.4%) | -$11.40 M(-129.2%) |
| Dec 2022 | $39.09 M(-794.9%) | - | - |
| Dec 2022 | - | $6.65 M(-194.2%) | $39.09 M(-14.9%) |
| Sep 2022 | - | -$7.06 M(-173.1%) | $45.92 M(-11.6%) |
| Jun 2022 | - | $9.66 M(-67.6%) | $51.97 M(+8.5%) |
| Mar 2022 | - | $29.84 M(+121.2%) | $47.89 M(-951.4%) |
| Dec 2021 | -$5.63 M(-91.6%) | $13.49 M(-1427.7%) | -$5.63 M(-83.3%) |
| Sep 2021 | - | -$1.02 M(-118.2%) | -$33.60 M(-19.6%) |
| Jun 2021 | - | $5.58 M(-123.6%) | -$41.82 M(-41.2%) |
| Mar 2021 | - | -$23.68 M(+63.4%) | -$71.15 M(+6.9%) |
| Dec 2020 | -$66.59 M(+25.4%) | -$14.49 M(+57.0%) | -$66.59 M(+0.2%) |
| Sep 2020 | - | -$9.23 M(-61.1%) | -$66.45 M(-3.2%) |
| Jun 2020 | - | -$23.75 M(+24.2%) | -$68.66 M(+13.1%) |
| Mar 2020 | - | -$19.12 M(+33.2%) | -$60.72 M(+14.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$53.10 M(-15.5%) | -$14.35 M(+25.4%) | -$53.10 M(+0.5%) |
| Sep 2019 | - | -$11.44 M(-27.7%) | -$52.83 M(-7.0%) |
| Jun 2019 | - | -$15.82 M(+37.6%) | -$56.80 M(-3.7%) |
| Mar 2019 | - | -$11.50 M(-18.3%) | -$58.99 M(-6.2%) |
| Dec 2018 | -$62.87 M(-0.8%) | -$14.07 M(-8.7%) | -$62.87 M(-7.3%) |
| Sep 2018 | - | -$15.41 M(-14.5%) | -$67.80 M(+1.8%) |
| Jun 2018 | - | -$18.02 M(+17.2%) | -$66.61 M(+4.0%) |
| Mar 2018 | - | -$15.37 M(-19.1%) | -$64.08 M(+1.1%) |
| Dec 2017 | -$63.37 M(+85.5%) | -$19.00 M(+33.6%) | -$63.37 M(+9.5%) |
| Sep 2017 | - | -$14.23 M(-8.1%) | -$57.87 M(+13.7%) |
| Jun 2017 | - | -$15.48 M(+5.6%) | -$50.88 M(+21.6%) |
| Mar 2017 | - | -$14.66 M(+8.6%) | -$41.83 M(+22.5%) |
| Dec 2016 | -$34.16 M(+47.3%) | -$13.50 M(+86.6%) | -$34.16 M(+25.5%) |
| Sep 2016 | - | -$7.24 M(+12.6%) | -$27.22 M(+8.2%) |
| Jun 2016 | - | -$6.43 M(-8.0%) | -$25.15 M(+1.4%) |
| Mar 2016 | - | -$6.99 M(+6.4%) | -$24.81 M(+7.0%) |
| Dec 2015 | -$23.18 M(+102.2%) | -$6.57 M(+27.0%) | -$23.18 M(+39.5%) |
| Sep 2015 | - | -$5.17 M(-15.0%) | -$16.62 M(+45.2%) |
| Jun 2015 | - | -$6.08 M(+13.5%) | -$11.45 M(+113.5%) |
| Mar 2015 | - | -$5.36 M | -$5.36 M |
| Dec 2014 | -$11.46 M | - | - |
FAQ
- What is Cartesian Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Cartesian Therapeutics?
- What is Cartesian Therapeutics annual EBITDA year-on-year change?
- What is Cartesian Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Cartesian Therapeutics?
- What is Cartesian Therapeutics quarterly EBITDA year-on-year change?
- What is Cartesian Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Cartesian Therapeutics?
- What is Cartesian Therapeutics TTM EBITDA year-on-year change?
What is Cartesian Therapeutics annual EBITDA?
The current annual EBITDA of RNAC is -$235.03 M
What is the all time high annual EBITDA for Cartesian Therapeutics?
Cartesian Therapeutics all-time high annual EBITDA is $39.09 M
What is Cartesian Therapeutics annual EBITDA year-on-year change?
Over the past year, RNAC annual EBITDA has changed by -$274.12 M (-701.29%)
What is Cartesian Therapeutics quarterly EBITDA?
The current quarterly EBITDA of RNAC is -$23.90 M
What is the all time high quarterly EBITDA for Cartesian Therapeutics?
Cartesian Therapeutics all-time high quarterly EBITDA is $29.84 M
What is Cartesian Therapeutics quarterly EBITDA year-on-year change?
Over the past year, RNAC quarterly EBITDA has changed by +$32.74 M (+57.81%)
What is Cartesian Therapeutics TTM EBITDA?
The current TTM EBITDA of RNAC is -$262.89 M
What is the all time high TTM EBITDA for Cartesian Therapeutics?
Cartesian Therapeutics all-time high TTM EBITDA is $51.97 M
What is Cartesian Therapeutics TTM EBITDA year-on-year change?
Over the past year, RNAC TTM EBITDA has changed by +$8.13 M (+3.00%)